8-K: Vivos Therapeutics Regains Nasdaq Equity Compliance

Vivos Therapeutics announced it has received confirmation from Nasdaq that it currently complies with the minimum stockholders equity requirement, averting immediate delisting concerns.

Summary

• Vivos Therapeutics received a letter from Nasdaq on October 20, 2026, confirming compliance with the minimum stockholders equity requirement (Listing Rule 5550(b)(1)).
• This compliance was achieved following the closing of an acquisition of an 11% equity interest in SOD Sciences, Inc. and a co-ownership interest in its pseudohypoxia test.
• As part of the SOD Sciences transaction, Vivos issued 12,000 shares of Series C Convertible Preferred Stock with an aggregate stated value of $12,000,000.
• This preferred stock is convertible into common stock, subject to certain caps and approvals, and is expected to increase stockholders equity by over $10 million.
• The company was previously notified of non-compliance with Nasdaq listing requirements in April 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a cautiously positive development, as the company has regained compliance with a key Nasdaq listing requirement, but the ongoing risk of delisting if future compliance is not maintained tempers the optimism.

Positives

• Regained compliance with Nasdaq's minimum stockholders equity requirement of $2.5 million.
• The acquisition of SOD Sciences, Inc. and its associated assets contributed to meeting the equity requirement.
• The issuance of Series C Convertible Preferred Stock is expected to significantly boost stockholders equity by over $10 million.
• Management is focused on executing its strategy to maintain compliance and grow the business.

Negatives

• The company must continue to demonstrate compliance with the minimum stockholders equity requirement upon filing its next periodic report to avoid potential delisting.
• There is a risk that the company's independent registered public accounting firm or Nasdaq may reach different conclusions regarding accounting treatment or stockholders equity.
• The company may not be able to maintain compliance with other Nasdaq listing requirements.

Risks

• Failure to evidence compliance with the minimum stockholders equity requirement upon filing the next periodic report.
• Disagreement between the company's accounting firm or Nasdaq regarding accounting treatment or stockholders equity.
• Inability to maintain compliance with other Nasdaq listing requirements.
• The anticipated benefits and revenue from the SOD Sciences transaction may not be realized.
• Failure to obtain stockholder approval for lifting the exchange cap on Series C Convertible Preferred Stock conversion.
• Dilution to existing stockholders upon conversion of the Series C Convertible Preferred Stock.

Future Outlook

The company must continue to demonstrate compliance with Nasdaq's minimum stockholders equity requirement upon filing its next periodic report. Failure to do so could lead to delisting. The company is executing its strategy to maintain compliance and grow its business, with the SOD Sciences transaction expected to contribute to equity and potentially revenue.

Management Comments

• "We are pleased to receive the compliance letter from Staff indicating that we are in compliance with Nasdaqs Stockholders Equity Standard required for continued listing on the Nasdaq Capital Market."
• "While the Company regained compliance with the stockholders equity requirement following the closing of the transaction with SOD, we continue executing our strategy to maintain compliance and grow our business."

Industry Context

StockSavvy.ai notes that maintaining listing on major exchanges like Nasdaq is critical for companies in the medical device and healthcare services sector to access capital and maintain investor confidence. Compliance issues can significantly impact a company's valuation and operational flexibility.

Comparison to Industry Standards

• Nasdaq Listing Rule 5550(b)(1) requires a minimum of $2.5 million in stockholders equity for continued listing.
• Companies in the medical technology sector often face scrutiny regarding financial health and listing compliance due to the capital-intensive nature of R&D and regulatory approvals.
• Competitors like Inspire Medical Systems (INSP) and ResMed (RMD) maintain higher levels of equity and market capitalization, demonstrating robust financial standing.

Related Party Transactions

• The acquisition of an 11% fully diluted equity interest in SOD Sciences, Inc. and a 50% undivided co-ownership interest in SODs pseudohypoxia early-warning test.

Stakeholder Impact

• Shareholders: Positive impact due to averted immediate delisting risk, but ongoing risk remains. Potential dilution from preferred stock conversion is a concern.
• Creditors: The company's continued listing on Nasdaq provides stability and access to capital markets, which is beneficial for creditors.
• Employees: Continued listing provides job security and operational stability.

Next Steps

• Demonstrate continued compliance with the minimum stockholders equity requirement upon filing the next periodic report.
• Seek stockholder approval for lifting the 19.99% exchange cap on the Series C Convertible Preferred Stock conversion.
• Continue executing the company's strategy to maintain compliance and grow the business.

Key Dates

Recommendation

The company has addressed a critical listing requirement, which is positive. However, the ongoing risk of delisting if future compliance is not maintained, coupled with potential dilution from preferred stock conversion, warrants a cautious 'hold' stance until sustained compliance and business growth are demonstrated.

Keywords

Nasdaq compliance, Stockholders Equity, Delisting risk, Convertible Preferred Stock, Acquisition, Sleep Apnea, Medical Device, Healthcare Services